Radiopharm Theranostics (ASX:RAD) completed the preclinical package for its radiotherapeutic product 161 terbium-labeled RAD 402, or 161Tb-Rad 402, according to a Tuesday filing with the Australian bourse.
Preclinical toxicology studies showed no adverse effects, while biodistribution reports showed minimal uptake in the kidney and bone marrow with high-prostate cancer tumor targeting in mice models, the filing said.
The biopharmaceutical firm is expected to conduct its first-in-human trials for the product by the second half of 2025, per the filing.
Company shares slumped 17% in recent Tuesday trade.
Price (AUD): $0.03, Change: $-0.01, Percent Change: -17.07%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.